Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?

Chris Sorel Mantsounga^{1

2}, Alan R Morrison^{1

2}

Affiliations

¹ Providence VA Medical Center, Providence, Rhode Island.
² Section of Cardiovascular Medicine, Department of Internal Medicine, Alpert Medical School at Brown University, Providence, Rhode Island.

Editorial

Chris Sorel Mantsounga et al. JACC Basic Transl Sci. 2019.

. 2019 Sep 23;4(5):592-595.

doi: 10.1016/j.jacbts.2019.08.003. eCollection 2019 Sep.

Chris Sorel Mantsounga^{1

2}, Alan R Morrison^{1

2}

¹ Providence VA Medical Center, Providence, Rhode Island.
² Section of Cardiovascular Medicine, Department of Internal Medicine, Alpert Medical School at Brown University, Providence, Rhode Island.

No abstract available

Keywords: cardiomyocyte; empagliflozin; endothelial cell; heart failure; microvasculature.

Figures

Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin.
Juni RP, Kuster DWD, Goebel M, Helmes M, Musters RJP, van der Velden J, Koolwijk P, Paulus WJ, van Hinsbergh VWM. Juni RP, et al. JACC Basic Transl Sci. 2019 Sep 4;4(5):575-591. doi: 10.1016/j.jacbts.2019.04.003. eCollection 2019 Sep. JACC Basic Transl Sci. 2019. PMID: 31768475 Free PMC article.

1. Benjamin E.J., Virani S.S., Callaway C.W. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492. - PubMed
1. Dunlay S.M., Roger V.L., Redfield M.M. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591–602. - PubMed
1. Zinman B., Wanner C., Lachin J.M. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. - PubMed
1. Fitchett D., Zinman B., Wanner C. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37:1526–1534. - PMC - PubMed
1. Boehringer Ingelheim, Eli Lilly Company. A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) (EMPEROR-Preserved). U.S. National Library of Medicine ClinicalTrials.gov. Feb 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT03057951. Accessed August 1, 2019.